Clinical Trials Browser

OTHER × siltuximab × Clear all

NCT05316116 2026-02-05

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Phase EARLY_PHASE1 Terminated

Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Phase 2 Recruiting

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT03315026 2025-11-04

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Phase 2 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT05684692 2025-10-30

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Phase 2 Recruiting

Schwannomatosis, Neurilemmoma, Pain, Chronic Pain

NCT04975555 2025-09-22

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04191421 2025-08-22

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

35 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Phase 2 Recruiting

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT06447376 2025-05-11

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Phase 1 Recruiting

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin

NCT06352866 2025-03-03

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Phase 2 Withdrawn

Cytokine Release Syndrome, Multiple Myeloma

NCT05665725 2025-01-31

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT05697510 2023-04-06

SILTUXILAM

Phase 1 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02805868 2016-10-24

Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Phase EARLY_PHASE1 Withdrawn

Classical hematologyLymphoidMyeloid

Anemia, Lymphoma, Follicular, Polycythemia Vera, Thrombocytopenia, Thrombocytosis, Primary Myelofibrosis